At the extraordinary general meeting held in Bioservo Technologies (BIOS) (the "Company") on December 14, 2023, it was decided that the Company would enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Companies Act, effective from the time of the Companies Registration Office's appointment of a liquidator.
Against this background, the Company has, on behalf of the Board of Directors, applied for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares will be announced through a separate press release shortly after the Company has received confirmation from Nasdaq First North.
For more information, please contact
Petter Bäckgren, CEO, Bioservo Technologies AB
Phone: +468 21 17 10
petter.backgren@bioservo.com (petter.backgren@bioservo.com )
Mikael Wester, Marketing Director, Bioservo Technologies AB
Phone: +468 21 17 10
mikael.wester@bioservo.com (mikael.wester@bioservo.com )
About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Kista north of Stockholm.
FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North Growth Market.
For more information, please visit www.bioservo.com